• Paul Hartmann first-half 2026 revenue climbed 3.3% organically to EUR 1.25 billion.
• Adjusted EBITDA rose EUR 25.9 million to EUR 151.7 million, lifting the adjusted EBITDA margin 1.7 percentage points to 12.1%.
• Wound Care grew on advanced wound care and U.S. demand, while reimbursement policy changes weighed; Complementary Group Divisions slipped on Kneipp.
• Full-year 2026 outlook maintained for moderate organic sales growth, with adjusted EBITDA seen at EUR 270 million-EUR 310 million.
• Hartmann flagged higher materials, energy and freight costs from the war in Iran as a second-half headwind; 2027 hit expected from new health-insurance rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paul Hartmann AG published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.